413 related articles for article (PubMed ID: 37071750)
1. Characterization of Pairs of Toxic and Nontoxic Misfolded Protein Oligomers Elucidates the Structural Determinants of Oligomer Toxicity in Protein Misfolding Diseases.
Limbocker R; Cremades N; Cascella R; Tessier PM; Vendruscolo M; Chiti F
Acc Chem Res; 2023 Jun; 56(12):1395-1405. PubMed ID: 37071750
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Measurement of the Affinity of Toxic and Nontoxic Misfolded Protein Oligomers for Lipid Bilayers and of its Modulation by Lipid Composition and Trodusquemine.
Errico S; Ramshini H; Capitini C; Canale C; Spaziano M; Barbut D; Calamai M; Zasloff M; Oropesa-Nuñez R; Vendruscolo M; Chiti F
ACS Chem Neurosci; 2021 Sep; 12(17):3189-3202. PubMed ID: 34382791
[TBL] [Abstract][Full Text] [Related]
3. Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches.
Salahuddin P; Fatima MT; Abdelhameed AS; Nusrat S; Khan RH
Eur J Med Chem; 2016 May; 114():41-58. PubMed ID: 26974374
[TBL] [Abstract][Full Text] [Related]
4. Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena.
Pain C; Dumont J; Dumoulin M
Biochimie; 2015 Apr; 111():82-106. PubMed ID: 25656912
[TBL] [Abstract][Full Text] [Related]
5. Elucidating the Role of Lipids in the Aggregation of Amyloidogenic Proteins.
Kurouski D
Acc Chem Res; 2023 Nov; 56(21):2898-2906. PubMed ID: 37824095
[TBL] [Abstract][Full Text] [Related]
6. Elucidating the Structures of Amyloid Oligomers with Macrocyclic β-Hairpin Peptides: Insights into Alzheimer's Disease and Other Amyloid Diseases.
Kreutzer AG; Nowick JS
Acc Chem Res; 2018 Mar; 51(3):706-718. PubMed ID: 29508987
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers.
Ugalde CL; Finkelstein DI; Lawson VA; Hill AF
J Neurochem; 2016 Oct; 139(2):162-180. PubMed ID: 27529376
[TBL] [Abstract][Full Text] [Related]
8. Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases.
Forloni G; Artuso V; La Vitola P; Balducci C
Mov Disord; 2016 Jun; 31(6):771-81. PubMed ID: 27030592
[TBL] [Abstract][Full Text] [Related]
9. Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies.
Cascella R; Bigi A; Cremades N; Cecchi C
Cell Mol Life Sci; 2022 Mar; 79(3):174. PubMed ID: 35244787
[TBL] [Abstract][Full Text] [Related]
10. Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits.
Stefani M
Prog Neurobiol; 2012 Dec; 99(3):226-45. PubMed ID: 22450705
[TBL] [Abstract][Full Text] [Related]
11. Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases.
Rinauro DJ; Chiti F; Vendruscolo M; Limbocker R
Mol Neurodegener; 2024 Feb; 19(1):20. PubMed ID: 38378578
[TBL] [Abstract][Full Text] [Related]
12. Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases.
Choi ML; Gandhi S
FEBS J; 2018 Oct; 285(19):3631-3644. PubMed ID: 29924502
[TBL] [Abstract][Full Text] [Related]
13. Role of water in protein aggregation and amyloid polymorphism.
Thirumalai D; Reddy G; Straub JE
Acc Chem Res; 2012 Jan; 45(1):83-92. PubMed ID: 21761818
[TBL] [Abstract][Full Text] [Related]
14. Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity.
Ladiwala AR; Litt J; Kane RS; Aucoin DS; Smith SO; Ranjan S; Davis J; Van Nostrand WE; Tessier PM
J Biol Chem; 2012 Jul; 287(29):24765-73. PubMed ID: 22547072
[TBL] [Abstract][Full Text] [Related]
15. Membrane disruption and early events in the aggregation of the diabetes related peptide IAPP from a molecular perspective.
Brender JR; Salamekh S; Ramamoorthy A
Acc Chem Res; 2012 Mar; 45(3):454-62. PubMed ID: 21942864
[TBL] [Abstract][Full Text] [Related]
16. α-Synuclein oligomers and fibrils: partners in crime in synucleinopathies.
Bigi A; Cascella R; Cecchi C
Neural Regen Res; 2023 Nov; 18(11):2332-2342. PubMed ID: 37282450
[TBL] [Abstract][Full Text] [Related]
17. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers.
Ehrnhoefer DE; Bieschke J; Boeddrich A; Herbst M; Masino L; Lurz R; Engemann S; Pastore A; Wanker EE
Nat Struct Mol Biol; 2008 Jun; 15(6):558-66. PubMed ID: 18511942
[TBL] [Abstract][Full Text] [Related]
18. The Toxicity of Misfolded Protein Oligomers Is Independent of Their Secondary Structure.
Vivoli Vega M; Cascella R; Chen SW; Fusco G; De Simone A; Dobson CM; Cecchi C; Chiti F
ACS Chem Biol; 2019 Jul; 14(7):1593-1600. PubMed ID: 31074957
[TBL] [Abstract][Full Text] [Related]
19. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
Hashimoto M; Rockenstein E; Crews L; Masliah E
Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
[TBL] [Abstract][Full Text] [Related]
20. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
Meredith SC
Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
